S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
Log in
NASDAQ:CRVS

Corvus Pharmaceuticals Competitors

$2.86
-0.02 (-0.69 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.83
Now: $2.86
$2.97
50-Day Range
$2.88
MA: $3.76
$4.77
52-Week Range
$1.01
Now: $2.86
$6.88
Volume929,906 shs
Average Volume1.12 million shs
Market Capitalization$80.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Competitors

Corvus Pharmaceuticals (NASDAQ:CRVS) Vs. RDHL, SESN, ONCR, GRAY, ALPN, and TFFP

Should you be buying CRVS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Corvus Pharmaceuticals, including RedHill Biopharma (RDHL), Sesen Bio (SESN), Oncorus (ONCR), Graybug Vision (GRAY), Alpine Immune Sciences (ALPN), and TFF Pharmaceuticals (TFFP).

Corvus Pharmaceuticals (NASDAQ:CRVS) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Corvus Pharmaceuticals has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Profitability

This table compares Corvus Pharmaceuticals and RedHill Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corvus PharmaceuticalsN/A-79.15%-63.99%
RedHill Biopharma-142.81%-152.19%-45.96%

Insider and Institutional Ownership

60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of RedHill Biopharma shares are owned by institutional investors. 45.1% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Corvus Pharmaceuticals and RedHill Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corvus Pharmaceuticals01202.67
RedHill Biopharma00303.00

Corvus Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 179.72%. RedHill Biopharma has a consensus target price of $20.00, suggesting a potential upside of 162.47%. Given Corvus Pharmaceuticals' higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than RedHill Biopharma.

Earnings & Valuation

This table compares Corvus Pharmaceuticals and RedHill Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80
RedHill Biopharma$6.29 million50.38$-42,300,000.00($1.40)-5.44

RedHill Biopharma has higher revenue and earnings than Corvus Pharmaceuticals. RedHill Biopharma is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Corvus Pharmaceuticals beats RedHill Biopharma on 7 of the 13 factors compared between the two stocks.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Sesen Bio (NASDAQ:SESN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Corvus Pharmaceuticals has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Sesen Bio has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Corvus Pharmaceuticals and Sesen Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corvus PharmaceuticalsN/A-79.15%-63.99%
Sesen BioN/AN/A-14.84%

Insider and Institutional Ownership

60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.8% of Sesen Bio shares are owned by institutional investors. 45.1% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Sesen Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Corvus Pharmaceuticals and Sesen Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corvus Pharmaceuticals01202.67
Sesen Bio00203.00

Corvus Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 179.72%. Sesen Bio has a consensus target price of $7.50, suggesting a potential upside of 206.12%. Given Sesen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Sesen Bio is more favorable than Corvus Pharmaceuticals.

Earnings & Valuation

This table compares Corvus Pharmaceuticals and Sesen Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.28

Sesen Bio is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Oncorus (NASDAQ:ONCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Profitability

This table compares Corvus Pharmaceuticals and Oncorus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corvus PharmaceuticalsN/A-79.15%-63.99%
OncorusN/AN/AN/A

Earnings & Valuation

This table compares Corvus Pharmaceuticals and Oncorus' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80
OncorusN/AN/A$-30,700,000.00N/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Corvus Pharmaceuticals and Oncorus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corvus Pharmaceuticals01202.67
Oncorus00303.00

Corvus Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 179.72%. Oncorus has a consensus target price of $32.3333, suggesting a potential upside of 131.61%. Given Corvus Pharmaceuticals' higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Oncorus.

Insider and Institutional Ownership

60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. 45.1% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oncorus beats Corvus Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Graybug Vision (NASDAQ:GRAY) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Insider and Institutional Ownership

70.7% of Graybug Vision shares are owned by institutional investors. Comparatively, 60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. 45.1% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Graybug Vision and Corvus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Graybug VisionN/AN/AN/A
Corvus PharmaceuticalsN/A-79.15%-63.99%

Earnings and Valuation

This table compares Graybug Vision and Corvus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graybug VisionN/AN/A$-37,040,000.00N/AN/A
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Graybug Vision and Corvus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Graybug Vision00703.00
Corvus Pharmaceuticals01202.67

Graybug Vision presently has a consensus price target of $34.7143, suggesting a potential upside of 135.35%. Corvus Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 179.72%. Given Corvus Pharmaceuticals' higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Graybug Vision.

Summary

Graybug Vision beats Corvus Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Alpine Immune Sciences (NASDAQ:ALPN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

52.9% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. 76.1% of Alpine Immune Sciences shares are owned by insiders. Comparatively, 45.1% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Alpine Immune Sciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.

Profitability

This table compares Alpine Immune Sciences and Corvus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alpine Immune Sciences-606.16%-80.38%-30.76%
Corvus PharmaceuticalsN/A-79.15%-63.99%

Earnings & Valuation

This table compares Alpine Immune Sciences and Corvus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpine Immune Sciences$1.74 million177.15$-41,850,000.00($2.28)-5.68
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80

Alpine Immune Sciences has higher revenue and earnings than Corvus Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Alpine Immune Sciences and Corvus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alpine Immune Sciences00603.00
Corvus Pharmaceuticals01202.67

Alpine Immune Sciences presently has a consensus price target of $19.40, suggesting a potential upside of 49.81%. Corvus Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 179.72%. Given Corvus Pharmaceuticals' higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Alpine Immune Sciences.

Summary

Corvus Pharmaceuticals beats Alpine Immune Sciences on 7 of the 13 factors compared between the two stocks.

TFF Pharmaceuticals (NASDAQ:TFFP) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

TFF Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.

Profitability

This table compares TFF Pharmaceuticals and Corvus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
Corvus PharmaceuticalsN/A-79.15%-63.99%

Earnings & Valuation

This table compares TFF Pharmaceuticals and Corvus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.56
Corvus PharmaceuticalsN/AN/A$-46,670,000.00($1.59)-1.80

TFF Pharmaceuticals is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for TFF Pharmaceuticals and Corvus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
Corvus Pharmaceuticals01202.67

TFF Pharmaceuticals presently has a consensus price target of $29.50, suggesting a potential upside of 116.91%. Corvus Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 179.72%. Given Corvus Pharmaceuticals' higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than TFF Pharmaceuticals.

Summary

TFF Pharmaceuticals beats Corvus Pharmaceuticals on 6 of the 11 factors compared between the two stocks.


Corvus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.62-2.8%$316.89 million$6.29 million-4.38Upcoming Earnings
Sesen Bio logo
SESN
Sesen Bio
1.2$2.45-1.2%$316.88 millionN/A-5.57Upcoming Earnings
Decrease in Short Interest
Oncorus logo
ONCR
Oncorus
1.6$13.96-1.1%$315.75 millionN/A0.00Upcoming Earnings
Graybug Vision logo
GRAY
Graybug Vision
2.0$14.75-7.5%$309.44 millionN/A0.00Analyst Revision
News Coverage
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$12.95-0.0%$308.25 million$1.74 million-8.99Insider Selling
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$13.60-0.1%$302.27 millionN/A-5.15Upcoming Earnings
NXTC
NextCure
1.6$10.97-3.1%$302.26 million$6.35 million-9.71Earnings Announcement
Analyst Revision
BELLUS Health logo
BLU
BELLUS Health
1.6$3.84-0.0%$300.81 million$30,000.00-6.51Decrease in Short Interest
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.10-1.4%$297.56 millionN/A-4.38
Theratechnologies logo
THTX
Theratechnologies
1.1$3.07-2.3%$288.09 million$63.22 million-9.90Increase in Short Interest
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.97-2.3%$276.22 millionN/A-4.78Upcoming Earnings
Increase in Short Interest
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.24-1.9%$275.11 million$6.01 million-2.63Earnings Announcement
Decrease in Short Interest
Kamada logo
KMDA
Kamada
1.4$6.08-0.3%$270.68 million$127.19 million12.67
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$10.69-4.6%$266.73 millionN/A-3.06
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.76-1.7%$265.39 million$9.48 million-0.30Upcoming Earnings
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.11-1.6%$264.51 million$11.94 million-7.38
Lannett logo
LCI
Lannett
2.0$6.35-2.8%$262.90 million$545.74 million-8.82
Larimar Therapeutics logo
LRMR
Larimar Therapeutics
1.7$17.02-1.4%$261.36 millionN/A-3.19Earnings Announcement
Analyst Revision
News Coverage
MediciNova logo
MNOV
MediciNova
1.2$5.36-1.3%$260.93 millionN/A0.00Decrease in Short Interest
Analyst Revision
Jaguar Health logo
JAGX
Jaguar Health
0.9$2.17-26.3%$255.67 million$5.78 million-0.31Gap Down
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$4.01-1.0%$254.37 millionN/A-2.84Upcoming Earnings
Analyst Revision
Galecto logo
GLTO
Galecto
1.6$9.73-4.9%$245.79 millionN/A0.00Upcoming Earnings
Gap Down
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.83-1.6%$238.68 millionN/A-8.32News Coverage
Tricida logo
TCDA
Tricida
1.9$4.69-1.1%$235.64 millionN/A-0.87
CTI BioPharma logo
CTIC
CTI BioPharma
1.3$3.07-3.3%$231.70 million$3.35 million-4.51Upcoming Earnings
Gap Down
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$4.72-2.5%$231.17 million$2.72 million-1.19
Cerecor logo
CERC
Cerecor
2.1$3.06-1.3%$229.23 million$6.75 million-10.20Upcoming Earnings
NuCana logo
NCNA
NuCana
1.5$4.70-6.8%$227.93 millionN/A-4.65Earnings Announcement
Gap Down
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.39-1.4%$227.69 million$22.05 million-2.78
BIVI
BioVie
1.7$16.36-9.7%$227.67 millionN/A0.00High Trading Volume
Increase in Short Interest
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$7.90-3.5%$227.59 million$28.80 million-5.10Upcoming Earnings
News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$7.74-1.7%$227.32 million$2.71 million-13.34Gap Up
Metacrine logo
MTCR
Metacrine
1.7$8.74-1.6%$226.86 millionN/A0.00Upcoming Earnings
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$4.47-3.6%$224.14 millionN/A-3.63Analyst Revision
Gap Up
OSMT
Osmotica Pharmaceuticals
1.1$3.54-0.6%$221.55 million$240.03 million-3.85
IMV logo
IMV
IMV
0.8$3.27-1.8%$219.38 million$430,000.00-7.11Gap Down
Novan logo
NOVN
Novan
0.9$1.44-0.7%$217.14 million$4.90 million-6.55Gap Down
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.4$1.42-2.8%$213.46 millionN/A0.00Gap Down
PANA
Panacea Acquisition
0.0$11.54-5.9%$212.98 millionN/A0.00High Trading Volume
Gap Down
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.4$5.40-0.2%$210.67 million$2.42 million-4.74Upcoming Earnings
Decrease in Short Interest
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.4$6.96-0.7%$207.57 millionN/A-2.96Gap Down
Abeona Therapeutics logo
ABEO
Abeona Therapeutics
1.6$2.10-4.3%$206.91 million$3 million-2.02Upcoming Earnings
Harrow Health logo
HROW
Harrow Health
1.7$8.03-1.0%$206.74 million$51.17 million-100.38Earnings Announcement
News Coverage
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$3.04-8.9%$206.36 million$1.71 million-6.61Upcoming Earnings
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.5$0.99-3.0%$205.58 million$2.18 million-0.67Increase in Short Interest
Gap Up
Enlivex Therapeutics logo
ENLV
Enlivex Therapeutics
1.4$12.98-0.1%$204.57 millionN/A-17.54Gap Down
NeuBase Therapeutics logo
NBSE
NeuBase Therapeutics
1.3$8.67-1.7%$200.97 millionN/A-9.63
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$7.29-0.1%$199.17 millionN/A-4.50
Genprex logo
GNPX
Genprex
1.2$4.56-7.5%$197.34 millionN/A-7.48Decrease in Short Interest
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.02-5.0%$197.02 millionN/A-2.42Upcoming Earnings
News Coverage
This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.